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Background: Denosumab has been shown to reduce tumor size and progression, reform mineralized bone, and
increase intralesional bone density in patients with giant cell tumor of bone (GCTB); however, radiologic assessment
of tumors in bone is challenging. The study objective was to assess tumor response to denosumab using
three different imaging parameters in a prespecified analysis in patients with GCTB from two phase 2 studies.
Methods: The studies enrolled adults and adolescents (skeletally mature and at least 12 years of age) with
radiographically measurable GCTB that were given denosumab 120 mg every 4 weeks, with additional doses
on days 8 and 15 of cycle 1. The proportion of patients with an objective tumor response was assessed using
either Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST), European Organisation for Research and
Treatment of Cancer response criteria (positron emission tomography [PET] scan criteria), or inverse Choi density/
size (ICDS) criteria. Target lesions were measured by computed tomography or magnetic resonance imaging
(both studies), PET (study 2 only), or plain film radiograph (study 2 only).
Results: Most patients (71.6%) had an objective tumor response by at least one response criteria. Per RECIST,
25.1% of patients had a response; per PET scan criteria, 96.2% had a response; per ICDS, 76.1% had a response.
68.5% had an objective tumor response ≥ 24 weeks. Using any criteria, crude incidence of response ranged from
56% (vertebrae/skull) to 91% (lung/soft tissue), and 98.2% had tumor control ≥ 24 weeks. Reduced PET avidity
appeared to be an early sign of response to denosumab treatment.
Conclusion: Modified PET scan criteria and ICDS criteria indicate that most patients show responses and higher benefit
rates than modified RECIST, and therefore may be useful for early assessment of response to denosumab.
Trial registration: ClinicalTrials.gov Clinical Trials Registry NCT00396279 (retrospectively registered November 6, 2006)
and NCT00680992 (retrospectively registered May 20, 2008).
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Giant cell tumor of bone (GCTB) is a histologically be-
nign bone tumor composed of mononuclear stromal and
multinucleated giant cells that exhibit osteoclastic activ-
ity, typically arising in the metaphyseal/epiphyseal por-
tions of long bones [1, 2]. GCTB causes significant bone
destruction, leading to pain, pathologic fracture, and im-
paired joint structure and functionality [3, 4]. Surgical
resection is the primary curative method for GCTB;
however, aggressive interventions, such as adjuvant ther-
apy with liquid nitrogen or phenol, are often required to
decrease morbidity, avoid amputation, and ensure ad-
equate local control [4, 5]. Effective treatment options
are limited for patients with lesions in locations not
amenable to surgical resection [4], and local recurrence
develops after several years in approximately 10–50%
and 5% of patients after intralesional treatment or wide
resection, respectively [5–8].
Constitutive activation of receptor activator of nu-
clear factor-kappa B (RANK) ligand maintains the
osteolytic phenotype in GCTB [9, 10]. Denosumab
(XGEVA®, Amgen Inc., Thousand Oaks, CA, USA), a
RANK ligand inhibitor, is a fully human monoclonal
antibody approved for the treatment of unresectable
GCTB or when resection may result in severe mor-
bidity. Denosumab treatment of GCTB prevents fur-
ther tumor progression, reduces tumor size, reforms
mineralized bone, and increases intralesional bone
density [10, 11].
Radiologic assessment of tumor response in bone tu-
mors presents unique challenges, and no uniform
radiographic assessment criteria to date have been ad-
vanced to specifically assess response in GCTB. To ad-
dress this challenge, our analysis combined imaging
assessment techniques and captured response elements
from three response evaluation measures widely
employed in the assessment of change in tumor burden
across a variety of tumor types, with modifications to
tailor the response measures specifically to the unique
properties of GCTB. Imaging records from two phase 2
clinical trials that supported denosumab registration
[10, 11] were analyzed with three imaging parameters
to measure the changes in lesion size and density, com-
pare available radiographic parameters, and assess
treatment response to denosumab in patients with
GCTB.
Methods
Study design
This analysis used data pooled from two phase 2,
open-label, single-arm, international, multicenter studies
of denosumab [10, 11] in skeletally mature patients
(≥ 12 years of age) with histologically confirmed GCTB
and radiographically measurable disease. Key exclusioncriteria included current use of alternative GCTB treat-
ments (e.g., radiation, chemotherapy, embolization, or
bisphosphonates). Study 1 [10] is complete; study 2 is on-
going [11]. In both studies, patients received 120 mg
denosumab subcutaneously every 4 weeks, with additional
loading doses on days 8 and 15 of the first treatment cycle
(i.e., month 1). Patients received denosumab until disease
progression and no clinical benefit, patient decision to
withdraw from the study, or until complete tumor resec-
tion. In study 2 [11], patients with complete tumor resec-
tion received an additional six doses of denosumab after
resection.
Imaging assessments
Patients with ≥ 1 evaluable time point assessment were
included in this analysis (Fig. 1). In study 1, computed
tomography (CT) or magnetic resonance imaging (MRI)
was required every 3 months [10], and in study 2, the
imaging modality and frequency followed the local
standard practice, which included plain film radiograph,
CT, MRI, and 2-deoxy-2-[18F]fluoro-D-glucose positron
emission tomography (18FDG-PET) [11]. Lesion images
were retrospectively reviewed centrally by experienced
bone radiologists blinded to investigator assessment.
The central review was performed using a charter-
specified, two-reader paradigm, with adjudication in case
of interpretation discordance [11]. Key parameters and
processes of the integrated, independent analysis of ob-
jective tumor response were agreed upon following con-
sultation with regulatory authorities.
All available CT, MRI, and whole-body 18FDG-PET
images were provided for the assessment of tumor re-
sponse and disease progression using prespecified cri-
teria (Table 1). Up to three response evaluation
parameters were used to capture the unique anatomic
and radiologic features of each lesion and response to
treatment. These included criteria for modified Re-
sponse Evaluation Criteria in Solid Tumors version
1.1 (RECIST), European Organisation for Research
and Treatment of Cancer (EORTC; referred to as
PET scan criteria), and inverse Choi density/size
(ICDS) as outlined in Table 1 [12–14]. Postbaseline
time points for assessment of tumor response, includ-
ing the length of therapy by the patient, are summa-
rized in Additional file 1: Figure S1.
Statistics
Statistical analyses were descriptive in nature, and only
summary statistics were presented. The analyses included
the proportion of patients with an objective tumor re-
sponse, time to first objective tumor response, duration of
objective tumor response, and the proportions of patients
with sustained (≥ 4, 12, and 24 weeks) objective tumor re-
sponse and tumor control (complete response [CR],
Fig. 1 CONSORT diagram
Table 1 Response criteria
Modified RECIST 1.1[13] Modified EORTC [12] ICDS [14]
CR Disappearance of all target lesions; all target
lymph nodes are < 10 mm in the short axis
Complete resolution of abnormal 18FDG uptake
within the tumor volume of all target lesions
to a level that is indistinguishable from
surrounding normal tissue
Disappearance of all disease
PR At least a 30% decrease in SLD using baseline
SLD as a reference
Reduction of the sum of the SUVmax by ≥ 15–
25% after 1 cycle and a decrease of ≥ 25%
compared with baseline after > 1 treatment
cycle
A decrease in size (%Δ Choi SLD) ≥ 10% or an
increase in CT density > 15% compared with
baseline, no new lesions, and no obvious
progression of nonmeasurable disease
SD Neither sufficient shrinkage of target lesions
to qualify for PR nor sufficient increase to
qualify for PD, taking as reference the nadir
SLD
%ΔΣ SUVmax increased by < 25% or decreased
by < 15% compared with baseline and no
visible extent of 18FDG tumor uptake
(> 20% in the longest dimension)
Does not meet the criteria for CR, PR, or PD; no
symptomatic deterioration attributed to tumor
progression
PD At least a 20% increase in the SLD of target
lesions, taking as reference the nadir SLD; in
addition to the relative increase of 20% in
SLD, the SLD must also demonstrate an
absolute increase of ≥ 5 mm
%ΔΣ SUVmax increased by ≥ 25% compared
with baseline scan, visible increase in the
extent of 18FDG uptake (> 20% in the longest
dimension) or the appearance of new 18FDG
uptake in metastatic lesions
An increase in unidimensional tumor size (Choi
SLD) ≥ 10% and does not meet the criteria for
PR using CT density; any new lesions identified
by CT/MRI; new intratumoral nodules or
increase in the size of existing intratumoral
nodules
UE A target lesion present at baseline that
subsequently became UE
18FDG-PET exam was unavailable or deemed
UE;a response will be UE unless unequivocal PD
is determined on the basis of the evaluable
target lesion
The CT/MRI exam is unavailable or deemed UE;
if a target lesion is deemed UE by density and
size measurement and the rules for PD do not
apply, a response of CR, PR, or SD cannot be
assigned for the time point and the response
will be UE
RECIST Response Evaluation Criteria in Solid Tumors, EORTC European Organisation for Research and Treatment of Cancer, ICDS inverse Choi density/size, CR
complete response, 18FDG-PET 2-deoxy-2- [18F]-fluorodeoxyglucose positron emission tomography, PR partial response, SLD sum of longest diameter, SUVmax
maximum standardized uptake value, SD stable disease, PD progressive disease CT computed tomography, MRI magnetic resonance imaging, UE unevaluable
aThe UE rate for this study was essentially 0
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Table 2 Baseline demographics and disease characteristics
Overall (N = 190)
Sex, n (%)
Female 105 (55)
Male 85 (45)
Age, median (Q1, Q3), years 33 (26, 43)
ECOG performance statusa, n (%)
0 106 (56)
1 76 (40)
2 6 (3)
Previous treatment
Resection/surgery 132 (70)
Bisphosphonates 38 (20)
Radiotherapy 37 (20)
Chemotherapy 21 (11)
GCTB disease type, n (%)
Recurrent unresectable 92 (48)
Primary unresectable 43 (23)
Recurrent resectable 29 (15)
Primary resectable 26 (14)
Location of target lesionb, n (%)
Pelvis/sacrum 61 (32)
Lower extremities 39 (21)
Lung 38 (20)
Spine 18 (10)
Upper extremities 17 (9)
Otherc 11 (6)
Skull/neck 5 (3)
Missing 1 (1)
Q quartile, ECOG Eastern Cooperative Oncology Group, GCTB giant cell tumor
of bone
aECOG missing for two patients
bBased on case report form
cIncludes other soft tissue and bone sites
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tumor response was defined as either CR or PR using any
of the three tumor response evaluation criteria. The pro-
portion of patients with an objective tumor response by
baseline target lesion location and the percentage changes
from baseline for lesion diameter and density were also
summarized.
Results
Patients
Of the 303 patients, 190 (study 1 [n = 27] and study 2
[n = 163]) were included in this analysis. Of these, 187
had measurable anatomic lesion size evaluable by CT,
26 had functional imaging by 18FDG-PET, and 176
had CT-evaluable lesions, assessed for Hounsfield unit
(HU) density and size, and were included in the
RECIST, PET scan criteria, and ICDS evaluations,
respectively.
Study 1 patients primarily had axial skeleton lesions
not amenable to surgery with curative intent. Study 2
patients were divided into resectable lesions for which
surgery could lead to significant morbidity (cohort 1)
and unresectable tumors (cohort 2). All patients had
radiographic evidence of active primary or recurrent
GCTB within the previous year, with target lesions dis-
tributed across the disease spectrum; pelvis/sacrum (n =
61; 32%), lower extremities (n = 39; 21%), and lung (n =
38; 20%) were common target lesion sites. Most patients
(70%) had prior GCTB resection/surgery, 20% had re-
ceived prior bisphosphonates, and 20% had received
prior radiotherapy (Table 2). Median (range) of time of
patient participation was 13.4 months (1.7–48.9); pa-
tients received a median (range) of 16 doses (4–54) of
denosumab. Baseline demographics and disease charac-
teristics for patients without evaluable imaging analysis
were similar to the population included in this analysis
(Amgen Inc., data on file).
Overall, 136/190 patients (71.6% [95% CI, 64.6–
77.9%]) had an objective tumor response (CR or PR) by
at least one response criteria. Per RECIST, 47/187 pa-
tients (25.1% [95% CI, 19.1–32.0%]) had a response; per
PET scan criteria, 25/26 patients (96.2% [95% CI, 80.4–
99.9%]) had a response; per ICDS, 134/176 patients
(76.1% [95% CI, 69.1–82.2%]) had a response (Table 3).
Using any response criteria, the median time to first ob-
jective tumor response (Kaplan-Meier estimate) was
about 3 months per PET scan and ICDS criteria and was
not estimable per RECIST. Overall, tumor responses
were sustained; most patients (68.5%) had an objective
tumor response for ≥ 24 weeks (Table 3). When analyzed
by study and cohort, response rates were similar for PET
scan criteria and ICDS (Table 3). Variations were ob-
served when using RECIST, which showed a lower rate
of response for study 1 (11%) than study 2 (28%). Withinstudy 2, the response rates per RECIST were 32% and
17% for cohort 1 and cohort 2, respectively (Table 3).
Similar results were observed for sustained objective
tumor responses at weeks 4, 12, and 24 (Table 3).
Objective tumor response by target lesion location
showed that the crude incidences of response (95% CI)
using any criteria were 14/24 (58.3% [36.6–77.9%]) for
pelvis, 22/37 (59.5% [42.1–75.2%]) for sacrum, 32/40
(80.0% [64.4–90.9%]) for lower extremity, 39/43 (90.7%
[77.9–97.4%]) for lung/soft tissue, 15/20 (75.0% [50.9–
91.3%]) for upper extremity, and 14/25 (56.0% [34.9–
75.6%]) for vertebrae/skull. Figure 2 shows CT images
before and after denosumab treatment in a patient with
sacral GCTB. Tumor control ≥ 24 weeks was observed
in 98.2% of patients using any criteria; similar rates were
observed for the other response criteria (Table 3).
Table 3 Objective tumor response resultsa
Overall best response RECIST 1.1 EORTC ICDS
Proportion of responders, n/N (%)
Overall 136/190 (71.6) 47/187 (25.1) 25/26 (96.2) 134/176 (76.1)
Study 1 20/27 (74.1) 3/27 (11.1) 15/16 (93.8) 18/23 (78.3)
Study 2 116/163 (71.2) 44/160 (27.5) 10/10 (100.0) 116/153 (75.8)
Cohort 1 76/114 (66.7) 36/113 (31.9) 4/4 (100.0) 76/105 (72.4)
Cohort 2 40/49 (81.6) 8/47 (17.0) 6/6 (100.0) 40/48 (83.3)
Median time to first OTR, months (95% CI)b 3.1 (2.89–3.65) NE (20.9–NE) 2.7 (1.64–2.79) 3.0 (2.79–3.48)
Patients with sustained OTR, n/N (%)
Overall
≥ 4 weeks 102/153 (66.7) 32/150 (21.3) 18/20 (90.0) 101/143 (70.6)
≥ 12 weeks 98/144 (68.1) 32/141 (22.7) 16/17 (94.1) 97/135 (71.9)
≥ 24 weeks 76/111 (68.5) 26/109 (23.9) 11/12 (91.7) 76/102 (74.5)
Study 1
≥ 4 weeks 15/24 (62.5) 2/24 (8.3) 11/13 (84.6) 13/20 (65.0)
≥ 12 weeks 14/20 (70.0) 2/20 (10.0) 10/11 (90.9) 13/17 (76.5)
≥ 24 weeks 12/17 (70.6) 2/17 (11.8) 8/9 (88.9) 12/14 (85.7)
Study 2
≥ 4 weeks 87/129 (67.4) 30/126 (23.8) 7/7 (100.0) 88/123 (71.5)
≥ 12 weeks 84/124 (67.7) 30/121 (24.8) 6/6 (100.0) 84/118 (71.2)
≥ 24 weeks 64/94 (68.1) 24/92 (26.1) 3/3 (100.0) 64/88 (72.7)
Cohort 1
≥ 4 weeks 59/91 (64.8) 25/90 (27.8) 3/3 (100.0) 60/85 (70.6)
≥ 12 weeks 56/87 (64.4) 25/86 (29.1) 3/3 (100.0) 57/81 (70.4)
≥ 24 weeks 49/73 (67.1) 22/73 (30.1) 2/2 (100.0) 50/67 (74.6)
Cohort 2
≥ 4 weeks 28/38 (73.7) 5/36 (13.9) 4/4 (100.0) 28/38 (73.7)
≥ 12 weeks 28/37 (75.7) 5/35 (14.3) 3/3 (100.0) 27/37 (73.0)
≥ 24 weeks 15/21 (71.4) 2/19 (10.5) 1/1 (100.0) 14/21 (66.7)
Patients with tumor controlc, %
≥ 4 weeks 148/153 (96.7) 145/150 (96.7) 19/20 (95.0) 139/143 (97.2)
≥ 12 weeks 139/144 (96.5) 137/141 (97.2) 17/17 (100.0) 131/135 (97.0)
≥ 24 weeks 109/111 (98.2) 108/109 (99.1) 12/12 (100.0) 101/102 (99.0)
RECIST Response Evaluation Criteria in Solid Tumors, EORTC European Organisation for Research and Treatment of Cancer, ICDS inverse Choi density/size; NE not
estimable, OTR objective tumor response
aPatients with at least one evaluable time point assessment
bKaplan-Meier estimate
cDefined as CR + PR + SD
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consistent with the advanced disease in the study popu-
lation (Table 4). Anatomic extent, measured by longest
diameter (LD), demonstrated that the greatest percent-
age decreases in size occurred ≤ 3 months on-study and
were consistent and sustained. Considering the best
percentage change in LD, arrangement in increasing
order of degree of response per the ICDS evaluation
(Additional file 1: Figure S2a) revealed a group of pa-
tients that did not respond to therapy, with an LDincrease ≥ 10% (n = 4, 2%); a second group of patients
with SD and LD changes ± 10% (n = 76, 43%); and a
third group of patients with an LD decreases ≥ 10% (n
= 95, 54%). For responders (defined by ≥ 10% reduction
in tumor size; Table 1) with a measurable decrease in
LD, there was an evenly graded distribution of best LD
reduction ranging from 11 to > 70%.
Using HU density as a response parameter, the best
percentage change in density for target lesions showed
that 99 of 124 patients (80%) had ≥ 15% increase and 25
a b
c d
Fig. 2 Sacral GCTB before and after treatment with denosumab. a Bone window and b soft tissue window pretreatment CT scan from August 14,
2009, through the level of the upper hip joints. There is extensive bone destruction and a large soft tissue mass that displaces the rectum. c
Bone window and d soft tissue window CT repeat scan on December 12, 2013 (about 4 years and 4 months later) following treatment with
denosumab (about 3 years and 10 months; first dose on January 21, 2010, and last dose on November 21, 2013). The soft tissue mass is now
negligible, and the bone is reconstituting. CT computed tomography; GCTB giant cell tumor of bone
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Figure S2b); 15% is the density cutoff for the response
per Choi gastrointestinal stromal tumor (GIST) cri-
teria [14]. HU evaluation showed that percentage in-
creases in tumor density ≤ 6 months on-study were
consistent and sustained; mean HU values rarely de-
creased once increases were observed, with medians
of 93 and 108 at postbaseline time point assessments
1 and 2, respectively. Time point assessments were ≥
24 weeks apart [11].
At baseline, the mean (SD) maximum standardized
uptake value (SUVmax) of
18FDG-PET in 26 patients
using PET scan criteria was 11.1 (4.7), indicative of high
metabolic activity in GCTB lesions before denosumab
treatment (Table 4). Almost 100% of lesions showed aTable 4 Baseline LD and SUVmax summary in patients with ≥ 1
evaluable time point assessment of 18FDG-PET avidity
n Mean SD Min Q1 Median Q3 Max
LD, mm 174 68.4 40.8 10.0 38.0 62.5 91.0 283.0
SUVmax 26 11.1 4.7 3.8 7.9 10.6 13.6 21.6
18FDG-PET 2-deoxy-2-[18F]-fluorodeoxyglucose positron emission tomography,
LD longest diameter, max maximum, min minimum, Q quartile, SUVmax
maximum standardized uptake valuerapid reduction in 18FDG-PET avidity at the earliest time
point assessment (Table 3). PET responsiveness did not
appear to vary with lesion location. Reduction in 18FDG-
PET avidity therefore appeared to be an early and uni-
versal sign of response to denosumab treatment.
Discussion
We observed impressive tumor control rates, with nearly
all patients with GCTB showing sustained tumor control
for ≥ 24 weeks, using any of the response criteria. In-
creases in lesion density by HU likely reflected the phar-
macodynamic response to denosumab treatment (i.e.,
suppression of osteolysis and increased formation of
dense fibro-osseous tissue and/or woven bone [9]). This
clinical benefit allows patients to defer or downstage
their planned surgical procedure when surgical resection
is likely to result in severe morbidity [15]. In contrast, a
purely size-based evaluation using RECIST is potentially
insensitive in assessing response in bone lesions with a
mixed osteolytic and expanding soft tissue component;
the size of GCTB tumors changes little with targeted
therapies. Therefore, an inverse modification of the
ICDS was used to evaluate both GCTB density and size;
either a decrease in size or an increase in density was
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in tumor size per LD are believed to reflect cytoreduc-
tion, in alignment with RECIST principles for solid
tumor assessment. The kinetics of GCTB responses to
denosumab therapy showed rapid cytoreduction that
peaked by 3 months and was maintained thereafter, with
responses of ≥ 24 weeks in nearly all patients. The Choi
criteria were developed to monitor response in a soft tis-
sue sarcoma undergoing targeted therapy where tumor
cell viability and radiological size reduction may be
uncoupled during the response to treatment [14]. Analo-
gous to GIST, in the setting of GCTB, we believe that
the ICDS criteria used in the present study perform as
pharmacodynamic markers of effect and may offer an
advantage to conventional RECIST.
In our study, patients had unresectable tumors or tu-
mors requiring highly invasive or disabling surgery in an
attempt to achieve surgical cure; therefore, there was a
large number of pelvic, spine, and pulmonary lesions
that complicated radiographic evaluation of response.
Using ICDS, four patients had a ≥ 10% increase in LD,
two of whom sustained increases in tumor size after
study enrollment but before administration of denosu-
mab. These two patients experienced sustained disease
control lasting several months while receiving denosu-
mab continuously, and for one patient, 12 additional
months of disease control following discontinuation of
denosumab. The remaining two patients had atypical
GCTB. One had multiostotic and metastatic GCTB with
lesions in the pelvis, rib, and lung at study entry and re-
ceived denosumab for 8 months before being lost to
follow-up. Multiostotic GCTB accounts for < 1% of all
GCTB and has a different clinical presentation than soli-
tary lesions; typically, patients are younger, suggesting a
germ-line component that confers susceptibility to the
disease [16–21]. The other patient with atypical GCTB
with an increased tumor size had a clinically aggressive
disease with ten previous attempts at surgical resection
before enrollment. While these patients met all histo-
logical entry criteria and had pathologically confirmed
GCTB, it remains unclear whether their atypical courses
before and during denosumab treatment suggest an ag-
gressive clinical variant of classical GCTB or an alterna-
tive diagnosis. Because true nonresponse to denosumab
in GCTB is rare, patients with nonresponse may deserve
more comprehensive sampling for histological disease
assessment. The best percentage change in density for
target lesions in the ICDS evaluation showed that 80% of
the 124 patients evaluable for density had a ≥ 15% in-
crease in density, reflecting the desired outcome of
denosumab therapy.
Our results confirm and extend findings reported in a
smaller study [22] where 88% patients (n = 17) had an ob-
jective tumor response using any response criteria afterdenosumab treatment (median duration of 13.1 months).
In the present study, the proportions of patients with an
objective tumor response were 35% per RECIST, 82% per
PET scan criteria, and 71% per ICDS criteria (size/density).
The median time to objective tumor response using any
of the response criteria was 3.0 months (95% CI, 2.9–3.1).
The benefit of denosumab in GCTB has already been
established [10, 11]; our results provide clinicians with
additional information on imaging and monitoring pa-
tients with GCTB treated with denosumab.
The single-arm study design limits our analysis; how-
ever, the central independent review of images was con-
ducted to minimize this limitation. Furthermore, this
study had a large number of unevaluable patients, there
was no protocol-defined imaging schedule or method-
ology (which is standard for this type of study), and
only a few PET scans were done, as PET was optional.
We also limited our definition of sustained tumor con-
trol to a time frame of 24 weeks, which may be consid-
ered short by some clinicians; however, there are no
well-established tumor response criteria for patients
with GCTB [22]. We also did not examine any associ-
ation between response and extent of prior treatment
or other factors. The retrospective nature of this ana-
lysis made obtaining historical images difficult.
There are inherent limitations associated with using
RECIST alone for assessment of denosumab response
in GCTB because of the sometimes modest reduction
in tumor size despite clinical benefit. Reduction in
18FDG-PET avidity predicted a favorable tumor re-
sponse and sustained tumor control with denosumab
treatment. Given the rarity of denosumab refractori-
ness in typical GCTB, new or continued high SUVmax
levels while on denosumab should alert clinicians to
the possibility of an aggressive clinical variant or an
alternate diagnosis such as sarcoma.
Our data do not suggest an increase in the risk of
osteosarcoma following denosumab treatment. There
are recent case studies of patients with GCTB treated
with denosumab who have developed osteosarcoma
[23, 24]; three patients were diagnosed with osteosar-
coma during denosumab treatment in primary reports
of the studies used for our analysis [10, 11]. Patients
with GCTB are at higher risk for developing osteosar-
coma than the general population, with approximately
2–5% of patients developing secondary sarcoma fol-
lowing radiotherapy or surgical resection [25–27].
There also remains the previously reported, equally
difficult task of identifying patients with small foci of
sarcomatous change within the large field of other-
wise benign-appearing GCTB [28]. The incidence of
pathologic fracture is up to 30% in patients with
GCTB; data to date do not indicate an increased rate
with denosumab [8, 29, 30].
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Modified PET scan criteria and ICDS criteria showed re-
sponses in most patients in our analysis, indicating a
substantially higher benefit rate compared to that
assessed by modified RECIST. PET or CT with ICDS
provided an early indication of treatment response.
Moreover, all response criteria indicated tumor control
≥ 24 weeks to denosumab. Loss of 18FDG-PET avidity
may have a dual role in both predicting long-term dis-
ease control and offering clinicians some reassurance
that there is not a focus of sarcoma with the GCTB le-
sion, which would likely remain 18FDG-PET avid despite
denosumab treatment. Further research is required to
determine the appropriate imaging technique to be used
longitudinally in a given patient, although many practi-
tioners favor a combination of plain radiographs and
CT. Regardless of the modality used, careful evaluation
of nonresponders is necessary.
Additional file
Additional file 1: Figure S1. Postbaseline time point assessments for
tumor response by study for patients with ≥ 1 evaluable time point
assessment. Per protocol, the sites were instructed to perform CT or
MRI scans of the lesion at baseline and quarterly during the treatment
period. 18FDG-PET scans were performed at the discretion of the investigator.
Because this was a retrospective, independent image review, no
specific acquisition parameters were provided. Sites were instructed
to use their standard acquisition parameters for CT, MRI, and 18FDG-
PET. Consistent use of the imaging modalities, parameters, and
contrast was recommended for reproducibility. CT computed
tomography, 18FDG‑PET 2-deoxy-2-[18F] fluoro-D-glucose positron
emission tomography; MRI magnetic resonance imaging. Figure S2.
(a) Best percentage change in SLD for target lesions in the ICDS
evaluation and (b) best percentage change in density for target
lesions in the ICDS evaluation. ICDS inverse Choi density/size; LD
longest diameter; SLD sum of longest diameter. (DOCX 233 kb)
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